Pfizer tops Q3 forecasts as total COVID-19 vaccine sales soar
Pfizer beat third-quarter expectations and raised its 2021 forecast again even as sales of its top product, the COVID-19 vaccine Comirnaty, slipped in the U.S. |!| Oklahoma City
Pfizer beat third-quarter expectations and raised its 2021 forecast again even as sales of its top product, the COVID-19 vaccine Comirnaty, slipped in the U.S. |!| Oklahoma City